Can ultrasensitive thyroglobulin immunoassays avoid the need for ultrasound in thyroid cancer follow-up?
Differentiated thyroid cancer
Follow-up
Thyroglobulin
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
10
08
2021
accepted:
31
10
2021
pubmed:
21
11
2021
medline:
24
3
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Differentiated thyroid cancer (DTC) is the most common endocrine neoplasm, with a rising incidence and a long life expectancy. It has recently been suggested that patients with low- and intermediate-risk DTC with a good response to treatment at one year could be followed up using only highly sensitive immunoassays for thyroglobulin (Tg). The aim of this study was to examine the serum Tg levels in a series of DTC patients with histologically proven persistent or recurrent diseases. The study involved 50 consecutive patients being routinely followed up at our center, whose clinical, histological, and biochemical data were retrospectively collected. The false-negative rate of ultrasensitive serum Tg assay was 14.3% (5/35) overall, and limited to anti-thyroglobulin autoantibodies (TgAb)-negative patients. Among them, only one patient had an excellent response to treatment at one-year follow-up and was diagnosed with a 4 mm recurrence, after more than seven years of periodic ultrasounds. The size of the neck lesion documented in the histological report was slightly larger in patients with detectable as opposed to negative Tg values (P < 0.05). Serum highly sensitive Tg is undetectable in a proportion of patients with a proven persistent or recurrent DTC. The reasons behind this phenomenon are still unknown. However, in low/intermediate-risk patients cured at one-year follow-up, highly sensitive Tg without neck US seems an appropriate strategy for patients' management.
Identifiants
pubmed: 34800265
doi: 10.1007/s12020-021-02936-2
pii: 10.1007/s12020-021-02936-2
doi:
Substances chimiques
Autoantibodies
0
anti-thyroid autoantibodies
0
Thyroglobulin
9010-34-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-845Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
J.J. Wiltshire, T.M. Drake, L. Uttley, S.P. Balasubramanian, Systematic review of trends in the incidence rates of thyroid cancer. Thyroid 26, 1541–1552 (2016). https://doi.org/10.1089/thy.2016.0100
doi: 10.1089/thy.2016.0100
pubmed: 27571228
E. Roti, E.C. degli Uberti, M. Bondanelli, L.E. Braverman, Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur. J. Endocrinol. 159, 659–673 (2008). https://doi.org/10.1530/EJE-07-0896
doi: 10.1530/EJE-07-0896
pubmed: 18713843
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016). https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Engl. J. Med 338, 297–306 (1998). https://doi.org/10.1056/nejm199801293380506
doi: 10.1056/nejm199801293380506
pubmed: 9445411
R.H. Grogan, S.P. Kaplan, H. Cao, R.E. Weiss, L.J. Degroot, C.A. Simon, O.M.A. Embia, P. Angelos, E.L. Kaplan, R.B. Schechter, A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154, 1436–46 (2013). https://doi.org/10.1016/j.surg.2013.07.008 .
doi: 10.1016/j.surg.2013.07.008
pubmed: 24075674
C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino, G. Costante, D. Meringolo, R. Bruno, F. Trulli et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013). https://doi.org/10.1210/jc.2012-3401
doi: 10.1210/jc.2012-3401
pubmed: 23293334
A. Frasoldati, M. Pesenti, M. Gallo, A. Caroggio, D. Salvo, R. Valcavi, Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97, 90–96 (2003). https://doi.org/10.1002/cncr.11031
doi: 10.1002/cncr.11031
pubmed: 12491509
J.L. Gray, G. Singh, L. Uttley, S.P. Balasubramanian, Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer—Where is the evidence? Endocrine 62, 26–33 (2018). https://doi.org/10.1007/s12020-018-1720-3
doi: 10.1007/s12020-018-1720-3
pubmed: 30128957
pmcid: 6153587
C.C. Lubitz, C.Y. Kong, P.M. McMahon, G.H. Daniels, Y. Chen, K.P. Economopoulos, G.S. Gazelle, M.C. Weinstein, Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer 120, 1345–1352 (2014). https://doi.org/10.1002/cncr.28562
doi: 10.1002/cncr.28562
pubmed: 24481684
S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1856–1883 (2019). https://doi.org/10.1093/annonc/mdz400
doi: 10.1093/annonc/mdz400
pubmed: 31549998
G. Grani, L. Lamartina, V. Cantisani, M. Maranghi, P. Lucia, C. Durante, Interobserver agreement of various thyroid imaging reporting and data systems. Endocr. Connect 7, 1–7 (2018). https://doi.org/10.1530/EC-17-0336
doi: 10.1530/EC-17-0336
pubmed: 29196301
L. Lamartina, G. Grani, M. Biffoni, L. Giacomelli, G. Costante, S. Lupo, M. Maranghi, K. Plasmati, M. Sponziello, F. Trulli et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 101, 3036–3044 (2016). https://doi.org/10.1210/jc.2016-1440
doi: 10.1210/jc.2016-1440
pubmed: 27186860
C. Spencer, J. LoPresti, S. Fatemi, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr. Opin. Endocrinol. Diabetes Obes. 21(21), 394–404 (2014). https://doi.org/10.1097/MED.0000000000000092
doi: 10.1097/MED.0000000000000092
pubmed: 25122493
pmcid: 4154792
A. Matrone, A. Faranda, F. Latrofa, C. Gambale, D. Stefani Donati, E. Molinaro, L. Agate, D. Viola, P. Piaggi, L. Torregrossa et al. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. J. Clin. Endocrinol. Metab. 105, e2845–e2852 (2020). https://doi.org/10.1210/clinem/dgaa297
doi: 10.1210/clinem/dgaa297
H.M. Dehbi, U. Mallick, J. Wadsley, K. Newbold, C. Harmer, A. Hackshaw, Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 7, 44–51 (2019). https://doi.org/10.1016/S2213-8587(18)30306-1
doi: 10.1016/S2213-8587(18)30306-1
pubmed: 30501974
pmcid: 6299255
G. Grani, V. Ramundo, R. Falcone, L. Lamartina, T. Montesano, M. Biffoni, L. Giacomelli, M. Sponziello, A. Verrienti, M. Schlumberger et al. Thyroid Cancer Patients with No Evidence of Disease: The Need for Repeat Neck Ultrasound. J. Clin. Endocrinol. Metab. 104, 4981–4989 (2019). https://doi.org/10.1210/jc.2019-00962
doi: 10.1210/jc.2019-00962
pubmed: 31206157
O.E. Okosieme, C. Evans, L. Moss, A.B. Parkes, L.D.K.E. Premawardhana, J.H. Lazarus, Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin. Chem. 51, 729–734 (2005). https://doi.org/10.1373/clinchem.2004.044511
doi: 10.1373/clinchem.2004.044511
pubmed: 15695326
L. Giovanella, F. Keller, L. Ceriani, R. Tozzoli, Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin. Chem. Lab Med 47, 952–954 (2019). https://doi.org/10.1515/CCLM.2009.230
doi: 10.1515/CCLM.2009.230
M. Schlumberger, S. Leboulleux, B. Catargi, D. Deandreis, S. Zerdoud, S. Bardet, D. Rusu, Y. Godbert, C. Buffet, C. Schvartz et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 6, 618–626 (2018). https://doi.org/10.1016/S2213-8587(18)30113-X
doi: 10.1016/S2213-8587(18)30113-X
pubmed: 29807824
P. Trimboli, F. D’Aurizio, R. Tozzoli, L. Giovanella, Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clin. Chem. Lab Med 55, 914–925 (2017). https://doi.org/10.1515/cclm-2016-0543
doi: 10.1515/cclm-2016-0543
pubmed: 27802177
R.M. Tuttle, B. Haugen, N.D. Perrier, Updated American Joint Committee on Cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27, 751–756 (2017). https://doi.org/10.1089/thy.2017.0102
doi: 10.1089/thy.2017.0102
pubmed: 28463585
pmcid: 5467103
R. Elisei, M. Schlumberger, A. Driedger, C. Reiners, R.T. Kloos, S.I. Sherman, B. Haugen, C. Corone, E. Molinaro, L. Grasso et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 94, 4171–4179 (2009). https://doi.org/10.1210/JC.2009-0869
doi: 10.1210/JC.2009-0869
pubmed: 19850694
M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, G. D’Azzò, D. Meringolo, E. Ferretti, R. Sacco et al. Follow-up of low risk patients with papillary thyroid cancer: Role of neck ultrasonography in detecting lymph node metastases. J. Clin. Endocrinol. Metab. 89, 3402–3407 (2004). https://doi.org/10.1210/jc.2003-031521
doi: 10.1210/jc.2003-031521
pubmed: 15240622
J.M. Han, W.B. Kim, J.H. Yim, W.G. Kim, T.Y. Kim, J.S. Ryu, G. Gong, T.Y. Sung, J.H. Yoon, S.J. Hong et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 22, 784–790 (2012). https://doi.org/10.1089/thy.2011.0322
doi: 10.1089/thy.2011.0322
pubmed: 22780573
pmcid: 3407383
Thyroid Tumors da Schlumberger, Martin; Pacini, Furio: Very Good Paperback (1999) | Solr Books. Available at: https://www.abebooks.it/Thyroid-Tumors-Schlumberger-Martin-Pacini-Furio/22525326953/bd [Accessed December 20, 2020]
R.T. Kloos, Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J. Clin. Endocrinol. Metab. 95, 5241–5248 (2010). https://doi.org/10.1210/jc.2010-1500
doi: 10.1210/jc.2010-1500
pubmed: 20843945
A. Bachelot, A.F. Cailleux, M. Klain, E. Baudin, M. Ricard, N. Bellon, B. Caillou, J.P. Travagli, M. Schlumberger, Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12, 707–711 (2002). https://doi.org/10.1089/105072502760258686
doi: 10.1089/105072502760258686
pubmed: 12225639